Related Experiment Videos
Pharmacokinetics of cisplatin and combination chemotherapy of cisplatin plus 5-FU
Japanese Journal of Clinical Oncology
|June 6, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2012
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).
Annals of oncology : official journal of the European Society for Medical Oncology·2012
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.
British journal of cancer·2011
Efficacy and safety of immunotherapy plus chemotherapy in elderly patients with advanced gastric cancer: a retrospective study.
Japanese journal of clinical oncology·2026
Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab.
Japanese journal of clinical oncology·2026
External validation of a three-variable Ewing sarcoma prognostic score and incremental value of the Glasgow prognostic score in adults: a multicenter cohort study.
Japanese journal of clinical oncology·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026